Pharmaceutical Profiles Study Advances Knowledge on Important Diabetes Drug
NOTTINGHAM, England, Sept. 17,2008--A new study has, for the first time, quantified the effect of the diabetes drug Byetta® (exenatide) on gastric emptying (GE). These significant data were generated for Eli Lilly by early clinical drug development specialist Pharmaceutical Profiles (Nottingham, UK), using the company’s expertise in gastrointestinal physiology and scintigraphy. It advances knowledge on both the effect and mode of action of Byetta®.
Scintigraphy is acknowledged as the gold-standard method for the assessment of GE. It allows simultaneous measurement of GE of solids and liquids, as well as the assessment of the distribution of contents within the stomach. The data generated helps to elucidate the potential for drug-drug interactions and evaluate the pharmacodynamic effect of drugs that influence gastric kinetics. This particular study further substantiated statements on the product label regarding reduction of the rate at which glucose appears in the circulation after meals with the administration of Byetta®.
Andy Rankin, CSO, Pharmaceutical Profiles, said: “Uniquely, scintigraphy provides a complete picture of gastric emptying, showing clearly what is happening with a drug. In today’s increasingly competitive market, generating quantitative data early in the development process informs decisions, saves time and money, and adds value to a candidate drug.”
Byetta® was developed to treat patients with type 2 diabetes who have not achieved adequate glucose control with other therapies. It helps the body control glucose levels without the need for dose adjustment due to food consumption or level of exercise. The only alternative would be injectable insulin.
To access the published study, visit: http://www.ncbi.nlm.nih.gov/pubmed/18675854
For more information about the work of Pharmaceutical Profiles, visit: www.pharmprofiles.com
Text ends
High resolution image is attached or available from Claire England, Kapler Communications claire@kapleronline.com quoting reference: PHA/JOB/031
About Pharmaceutical Profiles:
Pharmaceutical Profiles provides drug development support to most of the top pharmaceutical and biotechnology companies around the world.
The company specializes in early clinical drug development, with innovative technologies and expertise to optimize drug delivery and performance in the clinic.
World leading expertise in oral drug development has assisted the development of over 100 small molecules, peptides and protein therapeutics, including over 40 marketed drugs.
Unrivalled knowledge and experience in inhaled drug development has supported the development of the majority of inhaled drug delivery devices and formulations on the market today.
Pharmaceutical Profiles has around 100 highly qualified staff with a broad range of expertise. Facilities include a phase I clinical unit, a GMP facility for the manufacture of Investigational Medicinal Products (IMPs), and formulation R&D facilities all under one roof, just south of Nottingham in the UK.
For further information:
Press information
Richard Kent, Kapler Communications
Tel: +44 (0)1480 479 280 Fax: +44 (0) 1480 470 343
richard@kapleronline.com
Company contact:
Karen Jones PhD, Vice President, Marketing, Pharmaceutical Profiles Ltd
Tel: +44 (0)115 974 9000
karen.jones@pharmprofiles.com
Posted: September 2008
